MRK vs ABT
By Alex · Tickerpine
Merck & Co., Inc. vs Abbott Laboratories, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | MRK | ABT |
|---|---|---|
| Price | $148.78 | $101.29 |
| Market cap | $367.07B | $175.27B |
| P/E ratio | 119.0 | 32.8 |
| ROE | 6.96% | 10.58% |
| Profit margin | 4.77% | 11.65% |
| Revenue growth | 5.10% | 13.00% |
| Dividend yield | 2.29% | 2.49% |
| Beta | 0.23 | 0.59 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
MRK vs ABT in plain English
- MRK is the bigger company — about 2.1× the market cap of ABT.
- ABT is cheaper on earnings (P/E 32.8 vs 119.0).
- ABT earns a higher return on equity (11% vs 7%).
- ABT is growing revenue faster (13% vs 5%).
- ABT has the higher dividend yield (2.49% vs 2.29%).
How would $1,000 have done in each?
MRK return calculator
See what $1,000 in Merck & Co., Inc. would be worth today.
ABT return calculator
See what $1,000 in Abbott Laboratories would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.